Zafgen Inc., a biopharmaceutical company edicated to improving the health and well-being of patients affected by obesity and complex metabolic disorders has announced the initiation of a phase 3 trial of beloranib in Prader-Willi syndrome.
The trial will involve 84 patients and examine changes in hyperphagia and other metabolic parameters in children and adults with the genetic disease. Safety and efficacy will be assessed, as well as quality of life for patients and caregivers.
READ FULL ARTICLE From Yahoo! Finance